ARTICLE | Company News

Adheron, Roche deal

October 19, 2015 7:00 AM UTC

Roche will acquire Adheron, a developer of technology that disrupts cell adhesion via cell surface protein cadherin 11 ( Cad-11; CDH11). Adheron is investigating therapies for inflammatory and autoimmune disorders, including rheumatoid arthritis and fibrotic diseases. Adheron shareholders will receive $105 million up front and are eligible for up to $475 million in milestones. Adheron said it expects the deal to close “shortly.” ...